Biotie Therapies Corp.          Stock Exchange Release    13 February 2012 at 9.00 a.m.

Panu Miettinen appointed Chief Financial Officer of Biotie

Panu Miettinen, 43, has been appointed Chief Financial Officer (CFO) of Biotie Therapies Corp., effective March 15, 2012. He will become a member of the Group's management team and will report to Timo Veromaa, President and Chief Executive Officer. Panu Miettinen will be based at the Company's headquarters in Turku, Finland. Zack McNealy, current interim CFO, will resume his prior duties as Vice President, Finance and Administration at the Group's U.S. subsidiary.

Panu Miettinen, a Finnish native, has extensive expertise in finance, strategy, investor relations, and M&A. Previously Panu was the CFO of Elektrobit Corporation, a NASDAQ OMX Helsinki Ltd. listed company. Before joining Elektrobit Panu was a Management Consultant at Accenture and KPMG Consulting. Panu holds a M.Sc. (Economics) degree from Helsinki School of Economics, Finland.

Timo Veromaa, CEO of Biotie:

"I am very pleased that Panu is joining Biotie's management team and we look forward to his contributions to the organization. Panu is an experienced finance executive and his broad expertise from different industries will certainly be beneficial as Biotie becomes a more mature development company."

Turku, 13 February 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com  

Biotie

Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post traumatic stress disorder), and inflammatory and fibrotic liver disease.

The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing Authorization Application for Biotie's most advanced product, Selincro^TM (nalmefene) for alcohol dependence was filed in the EU by our partner H. Lundbeck A/S and was accepted for review by the European Medicines Agency in December 2011.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.